Tag Archives: brainstorm

Rasheda Ali is a Force to be reckoned with in the Fight Against Neurodegenerative Diseases

Log onto IFVNews.com, starting Saturday, March 31st to watch Rasheda Ali’s featured interview with IFV News.

New York, NY, USA – March 31, 2012 — IFV News host Marcella Palmer speaks with Rasheda Ali, daughter of legendary boxer Muhammad Ali, former Olympian and three-time World Heavyweight Champion suffering from Parkinson’s Disease. Rasheda discusses her role battling against some of the world’s toughest and most crippling neurocognitive diseases. She has traveled the world speaking to families coping with debilitating diseases such as: Parkinson’s, Alzheimer’s, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS) and Stroke and Spinal Cord injuries. Rasheda’s message is encouraging and enlightening, drawing on her personal involvement both as a family member and as a close affiliate to several organizations working to eliminate these diseases. Rasheda is currently affiliated with BrainStorm Cell Therapeutics. BrainStorm is an emerging and innovative biotech company located in Israel, dedicated to providing solutions for incurable neurodegenerative diseases.

About In Full View News (IFV News)
The IFV News Team is focused on bringing its viewers relevant business and financial information in an enjoyable comprehensive web based business news show format. A new webreport airs every Saturday at ifvnews.com. Viewers are encouraged to return daily for articles from trusted sources around the globe monitoring mid-cap, small-cap and micro-cap companies, as well as other medium/small businesses and entrepreneurs (SME). Featured news sources are Forbes, Business Week, BBC News, BusinessWire, PR Newswire, CNET, BusinessGreen and TechCrunch as well as other U.S. and International publications. Viewers are invited to contact IFV News regarding topics of interest. IFV News is a product of M.INK Productions® LLC, http://www.minkproductions.tv

About Rasheda Ali
In answering questions from her own children, Rasheda saw a clear need to provide answers to help other children understand why their loved ones behave a certain way because they have a neurological disorder and was inspired to write the book, I’ll Hold Your Hand So You Won’t Fall – A Child’s Guide to Parkinson’s Disease. She wanted her book to encourage dialogue and set an example of how clear communication within the family can overcome barriers and improve the quality of life for the whole family. Rasheda’s book has received praise from many influential as well as credible sources. One source, actor and Parkinson Disease advocate, Michael J. Fox, has lent his name to her book and commented, “Rasheda Ali brings home the profound liberation of a child’s innate willingness to accept disease without fear.” http://www.rashedaali.net

Rasheda is a tireless caregiver advocate on behalf of families fighting Parkinson’s disease and has spoken to many groups- including medical doctors, neurologists, and movement disorder specialists, caregivers and family members of those who suffer from Parkinson’s disease as well as school students, dignitaries, politicians, and social leaders.

The topic of her speech given worldwide is about coping with a Neurological condition and how it affects the family unit. She is a staunch advocate of stem cell research and travels all over the globe speaking about Parkinson’s disease in order to help give encouragement and hope for families struggling with the condition. Her travels have included venues all over the United States, Canada, London, Paris, Madrid, Luxembourg, Poland, Australia, New Zealand, South Africa, and Buenos Aires, Argentina. Her speaking appearances and book signings have raised hundreds of thousands of dollars and more for Parkinson disease organizations all over the globe.

About BrainStorm Cell Therapeutics
BrainStorm is an emerging company developing stem cell therapeutic products based on breakthrough technologies http://www.brainstorm-cell.com. BrainStorm’s core technology, NurOwn™, was developed through a collaboration between prominent neurologist, Prof. Eldad Melamed, Head of Neurology of the Rabin Medical Center and member of the Scientific Committee of Michael J. Fox Foundation for Parkinson’s Research and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University.

This scientific team is among the first to have successfully demonstrated the physiological release of dopamine from in vitro differentiated bone marrow cells. Moreover, in research conducted by this team, implantation of these cells into the brains of animal models that had been induced to Parkinsonian behavior markedly improved their symptoms. BrainStorm intends to apply the patent-pending technology to the development of innovative autologous cell therapeutic products, NurOwn™, for treatment of neurological diseases.

BrainStorm holds exclusive worldwide rights to commercialize the NurOwn™ technology, through a licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University.

Media contact for IFV News:
Marion Palmer
M.INK Productions® LLC
347.746.6465

Media contact for Brainstorm Cell:
Janet Vasquez
IRG, LLC – Wholly owned subsidiary of DirectMarkets Group, LLC
1251 Avenue of the Americas, 20th Floor
New York, NY 10020
Tel: 212-825-3210
E-Mail: jvasquez@investorrelationsgroup.com
Web: http://www.irgnews.com

BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis

Proposed Trial Will Build on NurOwn(TM) Platform to Meet Unmet Needs of Patients with Neurodegenerative Disorders.

NEW YORK & PETACH TIKVAH, ISRAEL, Mar 13, 2012 — BrainStorm Cell Therapeutics Inc., a developer of adult stem cell technologies and CNS therapeutics, announces plans to initiate a preclinical study assessing the efficacy of its NurOwn(TM) stem cell technology in patients with Multiple Sclerosis (MS). Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivo experiments, and the Company is working to advance MS into preclinical development in Q2 2012.

Based on initial promising pre-clinical data published by the Company’s Chief Scientist, Prof. Daniel Offen of Tel Aviv University, BrainStorm has decided to explore MS as an additional indication for its NurOwn technology. The Company will draw plans to initiate pre-clinical safety trials, after which it will seek a leading medical center specializing in MS for clinical trials.

“We have been focused on growing our pipeline of indications using our NurOwn(TM) stem-cell technology,” commented Dr. Adrian Harel, Acting CEO of BrainStorm Cell Therapeutics. “As we continue our ongoing trials to evaluate the safety, tolerability and therapeutic effects of NurOwn(TM) in ALS patients, we have determined through positive preliminary animal data that MS will be the next indication to pursue using our technology.”

About NurOwn(TM) BrainStorm’s core technology, NurOwn(TM), is based on the scientific achievements of Professor Eldad Melamed, former Head of Neurology, Rabin Medical Center, and Tel-Aviv University, and Professor Daniel Offen, Head of the Neuroscience Laboratory, Felsenstein Medical Research Center at the Tel-Aviv University.

The NurOwn(TM) technology processes adult human mesenchymal stem cells that are present in bone marrow and are capable of self-renewal as well as differentiation into many cell types. The research team is among the first to have successfully achieved the in-vitro differentiation of adult bone marrow cells (animal and human) into cells capable of releasing neurotrophic factors, such as glial-derived neurotrophic factor (GDNF), by means of a specific differentiation-inducing culture medium.

About Multiple Sclerosis (MS)
Multiple sclerosis (MS) is believed to be an autoimmune disorder that affects the central nervous system (CNS). Autoimmune means that the body’s immune system mistakenly attacks its own tissue, in this case, the tissues of the CNS. With MS, autoimmune damage to neurons disrupts the body’s ability to send and receive signals, thus causing MS-related symptoms.Symptoms may vary due to the location and extent of the damage. Worldwide, MS may affect more than 2 million individuals, including approximately 400,000 people in the United States.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn(TM) technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel-Aviv University. For more information, visit the company’s website at http://www.brainstorm-cell.com.

Media Contact:
Janet Vasquez
IRG, LLC
1251 Avenue of the Americas, 20th Floor
New York, NY 10020
212-825-3210
jvasquez@investorrelationsgroup.com
http://www.irgnews.com